74 results about "Stage I Esophageal Squamous Cell Carcinoma" patented technology

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and / or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and / or the vaccine.

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention provides a four-autoantibody combined detection kit for diagnosing an early esophageal squamous cancer and application thereof. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer comprises a solid substrate and antigen protein which coats the solid substrate; and the antigen protein comprises TP53, HRAS, CTAG1A and NSG1. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer, provided by the invention, has the advantages that the TP53, the HRAS, the CTAG1A and the NSG1 are firstly adopted as acombination to be used for early diagnosis of ESCC, higher sensibility and higher specificity are realized, the detection kit is conducive to further improvement of serologic screening quality of ESCC early diagnosis, and therefore, the cure rate and survival rate of patients are further promoted.

The invention discloses a diagnosis marker suitable for an early-stage esophageal squamous cell cancer diagnosis and a screening method of the diagnosis marker. Twenty five kinds of serum metabolic markers and ten relevant metabolic pathways are discovered; through the combination of the twenty five kinds of serum metabolic markers, the diagnosis marker used for an esophagus cancer diagnosis can be obtained. The screening method of the diagnosis marker has high operability; the diagnosis marker can be used for building a diagnosis model; the diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for a late-stage esophagus cancer diagnosis and is also suitable for the early-stage esophagus cancer diagnosis. The diagnosis model built by adopting the diagnosis marker provided by the invention has the advantages that the diagnosis can be realized only through blood sampling; the noninvasive effect is achieved; the cost is low; the modern internal invasive diagnosis mode can be well replaced; the pain of a patient is greatly reduced; in addition, the diagnosis speed is high; convenience is realized; the required time is short; the work efficiency is improved; the early discovery and early treatment of an esophagus cancer can be favorably realized; good clinic use and popularization value is realized.

The invention belongs to the technical field of biotechnology, and discloses a miRNA combination used for detecting esophageal squamous cell carcinoma and application thereof. The miRNA combination comprises miR-22, miR-127-3p, miR-148b and miR-223, and the miRNA combination can further comprise one or more of miR-10a, miR-100 and miR-133a. A kit comprises a probe combination of the miRNAs. The miRNA combination and the probe combination thereof provided by the invention can be used for detecting the esophageal squamous cell carcinoma, and can be used as a diagnosis marker for improving the accuracy of detection, improving the insuperable low specificity and low sensitivity, caused by individual difference, of a single marker, and improving a clinical detectable rate remarkably by combining other detection indicators and clinical symptoms of a patient, so the miRNA combination and the probe combination thereof become an effective means for early diagnosis of the esophageal squamous cell carcinoma. Due to the adoption of the miRNA combination, a noninvasive serological test is adopted so as to bring convenience to clinical promotion.

The invention relates to an esophageal squamous cell carcinoma autoantibody molecular marker model and an application thereof. The molecular model mainly comprises an ALDOA autoantibody, an ENO1 autoantibody, a p53 autoantibody, and an NY-ESO-1 autoantibody, and can be used for preparing a kit for distinguishing esophageal squamous carcinoma patients and healthy medical examiners. The kit for detecting esophageal squamous cell carcinoma patients mainly comprises recombinant ALDOAD protein, recombinant ENO1 protein, recombinant p53 protein, and recombinant NY-ESO-1 protein. According to the esophageal squamous cell carcinoma autoantibody molecular marker model and the application thereof, the ENO1 autoantibody is found to be elevated in serum level in the esophageal squamous carcinoma patients for the first time, and is jointly detected with the ALDOA autoantibody, the p53 autoantibody, and the NY-ESO-1 autoantibody for distinguishing the esophageal squamous cell carcinoma patients andthe healthy medical examiners, and has a better distinguishing effect than a single index detection; and in addition, the detection method adopted by the invention is an enzyme-linked immunosorbent assay indirect method, is simple and convenient to implement, has good sensitivity and specificity, and is a method which is mature and reliable and can be widely used in base layer hospitals.

The invention discloses applications of miR-455-3p in the diagnosis, treatment, and prognosis of esophageal squamous cancer. The inventor finds that the obviously low survival rate of ESCC patients is related with the high expression of miR-455-3p in ESCC patients. The in-vitro and in-vivo experiment results show that miR-455-3p is capable of promoting the malignant progression of ESCC, by inhibiting the expression of miR-455-3p, the ESCC stem cell characteristics can be inhibited, and the sensitivity of ESCC stem cells to chemotherapy drugs is enhanced; so an expression inhibitor of miR-455-3p can inhibit the tumor stem cells, and is capable of inhibiting the tumor stem cell characteristics and enhancing the sensitivity of the cancer stem cells to chemotherapy drugs. The invention finds the expression of miR-455-3p in cancer patients for the first time, and the expression can be used as auxiliary diagnosis and / or prognosis of ESCC. The invention provides a novel diagnosis method, a novel treatment method, and a pharmaceutical drug screening platform for tumor diseases.

The invention belongs to the technical field of biotechnology and medical technology, and relates to a marker ALDOA autoantibody for distinguishing between esophageal squamous cell carcinoma patients and normal persons, and a detection method and applications thereof. In the invention, the serum proteome research technology is adopted to identify a new marker ALDOA autoantibody for esophageal squamous cell carcinoma. Purified ALDOA proteins are subjected to ELISA analysis for detecting expression level of the ALDOA autoantibody in serums of esophageal squamous cell carcinoma patients and normal persons, and the results indicate that the level of the ALDOA autoantibody in the serum of esophageal squamous cell carcinoma patients is obviously higher than that of the normal persons. The ALDOA autoantibody of the invention can serve as the marker of the esophageal squamous cell carcinoma and can be used in the diagnosis of the esophageal squamous cell carcinoma.

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention belongs to the technical field of biological medicine, provides an application of ZNF750 in screening a targeted medicine for treating esophageal squamous cell carcinoma, provides a novel target for blocking the metastasis of esophageal squamous cell carcinoma cells or inhibiting the change of the esophageal squamous cell carcinoma cells, and provides a treatment clue for patients with esophageal squamous cell carcinoma with ZNF750 variation. The invention provides the application of ZNF750 in screening the targeted medicine for treating the esophageal squamous cell carcinoma. The esophageal squamous cell carcinoma is esophageal squamous cell carcinoma with ZNF750 gene mutation, deletion, inactivation variation or ZNF750 low expression. The targeted medicine treats the esophageal squamous cell carcinoma by inhibiting or blocking angiogenesis-related gene expression of a downstream target gene of ZNF750. The detection of ZNF750 mutation can divide the patients with esophageal squamous cell carcinoma into two groups of mutant type and wild type, and the medicine targeted to KDR can provide effective treatment selection for the patients with ZNF750 inactivation variationand improve the clinical prognosis.

The invention relates to an esophageal squamous cell carcinoma microenvironmental cell marker molecular model and application thereof. The molecular model mainly comprises a-SMA+ (invasive frontier) fibroblasts, CD163+ (interstitial) macrophages, CD117+ (protogenic layer) mastocytes and CD117+ (invasion frontier) mastocytes. The molecular model can be used to predict the prognosis of patients withesophageal squamous carcinoma and group adjuvant treatment sensitivity groups. A kit mainly includes an anti-CD117 protein antibody, an anti-CD163 protein antibody and an anti-a-SMA protein antibody.According to the invention, the combination of three molecules combined with histopathological features predicts patients' prognosis, which has a higher predictive effect than single index detectionand clearly distinguishes patients with esophageal squamous carcinoma adjuvant treatment sensitivity; an immune tissue chemical hypersensitivity two-step method on which the molecular model is based is a mature and reliable method which can be widely used in primary hospitals; and compared with international TNM staging, the molecular model has a higher predictive effect, and is simpler, easier, more sensitive and more specific.

The invention discloses an application of lnc_XR_242314.2 and lnc_TCONS_00011689 in blood for combined diagnosis of esophageal squamous cell carcinoma. The nucleotide sequence of an lnc_XR_242314.2 molecular marker is SEQ ID NO. 1, and the nucleotide sequence of an lnc_TCONS_00011689 molecular marker is SEQ ID NO. 2. The discovery, detection, and application of lnc_XR_242314.2 and lnc_TCONS_00011689 are related, and a specific detection primer for real-time quantitative PCR can be designed and synthesized. The lnc_XR_242314.2 and lnc_TCONS_00011689 in the blood can be used as plasma markers for ESCC patients, and the combination effect is better. The above method of examination is easily accepted by a subject and can be an effective means of early diagnosis, determination of disease progression and prognosis assessment of the ESCC patients.

The invention discloses application of a circ_SLC7A5 molecular marker in blood in diagnosing esophageal squamous carcinoma and prognosis, and relates to discovery, detection and application of the circ_SLC7A5 molecular marker. A specific detection primer for real-time quantitative PRC is designed and synthesized. Circ_SLC7A5 in the blood can serve as a plasma marker for ESCC patients, aiming at the status quo that a target group of people have poor compliance on esophagus cancer endoscope screening, and most of esophageal squamous carcinoma patients with definite diagnosis in clinic are in themiddle and advanced stage, ideal molecular early-warning signals are found out in the esophagus squamous cell canceration process, endoscopy is targetedly carried out, the pathology is conformed, sothat the pain of the patients is alleviated, excessive medical treatment is avoided, and medical resources are saved.

The invention discloses application of tegaserod maleate in preparation of an antitumor drug. The drug tegaserod maleate has a CAS number of 189188-57-6, a chemical name of 2-[(-5 methoxy-1H-indole-3-group) methylene]-N-pentylcarbazide maleate, a molecular formula of C20H27N5O5, and a molecular weight of 417.46. Experiments prove that when the tegaserod maleate is used for esophageal squamous cellcarcinoma cells (KYSE150 cells and KYSE450 cells), the tegaserod maleate can play a role in inhibiting the growth of esophageal squamous cell carcinoma cells, and the suitable concentration of the tegaserod maleate in inhibiting the proliferation of esophageal squamous cell carcinoma cells and the number and size of clone formation is 0.25-2.5 micrometers.

The invention relates to the use of a microRNA-548k inhibitor in treatment and / or prevention of the esophageal squamous cancer. Further the invention relates to the microRNA-548k as a molecule marker used for diagnosing the esophageal squamous cancer.

The invention provides an immune-enhancing antineoplastic collagen composition as well as a preparation method and an application thereof. The composition is characterized by consisting of antineoplastic factors, collagen, polysaccharide substances and active factors. The composition is applicable to, but not limited in, cells for treating breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostatic cancer, bladder cancer, melanoma, lung cancer, stomach cancer, liver cancer, head and neck squamous cell carcinoma, carcinoma of uterine cervix, renal cell carcinoma, thyroid cancer, acute myeloid leukemia, myeloma, esophageal squamous cancer, lymphoma and the like.

The invention discloses a diagnosis marker suitable for an early-stage esophageal squamous cell cancer diagnosis. The diagnosis marker is a composition of two or more than two kinds of materials from the following five kinds of serum metabolic markers including L-tyrosine, L-tryptophan, glycocholic acid, taurocholate and cortisol. When the diagnosis marker provided by the invention is adopted, a diagnosis model can be built. The diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for late-stage and early-stage esophagus cancer diagnoses, and has good clinic use and popularization value.

The invention relates to the technical field of biological medicine, and provides a molecular marker for prognosis prediction of esophageal squamous cell carcinoma and application thereof. An RNA-seq data set is used for screening out four circular RNA gene combinations with the maximum AUC value, and the four circular RNA gene combinations are named as 4-circular RNA markers. The study shows that the 4-circular RNA markers can independently predict the survival of ESCC patients; the accuracy of the traditional TNM staging evaluation on the ESCC patient prognosis is obviously improved; and the 4-circular RNA markers can be used as reference judging indexes of the esophageal squamous cell carcinoma prognosis survival time and prognosis survival risk prediction reference. Through studying the relationship between the 4-circular RNA markers and the clinical prognosis of the esophageal squamous cell carcinoma patients, a novel marker is provided for the esophageal squamous cell carcinoma prognosis judgment, so that the timely intervention treatment on the esophageal squamous cell carcinoma patients can be improved; the clinical prognosis of the patients is improved; and the important significance is realized in the clinical practice.

The disclosure relates to the use of anti-PD-1 antibodies in combination with paclitaxel and platinum compounds in preparation of medicaments for the treatment of esophageal cancer. Specifically, theinvention provides application of an anti-PD-1 antibody or an antigen binding fragment thereof in combination with a paclitaxel compound and a platinum compound to prepare drugs for treating the esophageal squamous cell carcinoma or esophageal adenosine monophosphate carcinoma. The scheme shows a synergistic effect of drug combination.

The invention relates to the use of an FAM135B inhibitor in treatment and / or prevention of the esophageal squamous cancer. Further the invention relates to the use of the FAM135B genome mutation in diagnosis and / or prognosis of the esophageal squamous cancer.

The invention discloses application of a reagent for inhibiting the activity of protein kinase CLK in preparation of a medicine for treating or improving esophageal squamous cell carcinoma, and relates to the technical field of tumor detection. Analysis is conducted on an esophageal squamous cell carcinoma tumor sample, it is found that the activity of the protein kinase CLK in an ESCC patient is abnormally increased, and by inhibiting the activity of the CLK, the purpose of effectively treating or improving ESCC can be achieved, and a new way is provided for treatment and mechanism research of ESCC.

The invention discloses an application of otilonium bromide to preparation of antitumor medicines. The otilonium bromide is chemically named as N,N-diethyl-N-methyl-2-[[4[[2- (octyl ) benzoyl]amino]benzoyl] oxyl] ethanaminium bromide, CAS No. is 26095-59-0, the molecular formula is C29H43BrN2O4, and the molecular weight is 563.56. The antitumor medicines are medicines for treating esophagus canceror gastric cancer. Experiments confirm that when the otilonium bromide is used for esophageal squamous cell carcinoma cells (KYSE150 cells and KYSE450 cells) or gastric cancer cells ( HGC27 cells andAGS cells), the otilonium bromide can achieve the effects of restraining growth and transformation of the esophageal squamous cell carcinoma cells or the gastric cancer cells, and the appropriate concentration of the otilonium bromide for restraining proliferation and transformation of the esophageal squamous cell carcinoma cells or the gastric cancer cells is 2.5-20 [mu]M.

The invention discloses the use of cyperazulenone for preparing a drug for inhibiting SIRT1 gene expression for treating esophageal squamous cell carcinoma. The cyperazulenone and cyperene-2,5,8-triolare effective SIRT1 gene expression inhibitors, and can effectively inhibit the migration and invasion of esophageal squamous cell carcinoma by inhibiting the expression of SIRT1 gene, so the cyperazulenone and cyperene-2,5,8-triol can be developed as a drug to treat the metastasis of esophageal squamous cell carcinoma.

The invention discloses a detection reagent and kit used for esophageal cancer diagnosis or auxiliary diagnosis, is used for carrying out DNA methylation level detection on the full length and partial region of SEQ ID NO.22 or a complementary sequence thereof, can be used for diagnosis and auxiliary diagnosis of esophageal cancer patients, and is especially suitable for detection diagnosis / auxiliary diagnosis of esophageal squamous cell carcinoma. The detection reagent and kit can be used for esophageal cancer patients in different stages, has good sensitivity and specificity, can adopt tissue samples and plasma samples as monitoring samples, and has great significance in early diagnosis of the esophageal cancer and improvement of patient prognosis.

The invention relates to the technical field of medical diagnosis, and discloses a mechanism of long non-coding RNA gas-5 to regulate miRNA-196a and also discloses application of the mechanism of thelong non-coding RNA Gas-5 to regulate miRNA-196a in kits and chips for diagnosing and treating esophageal cancer. According to the invention, by taking esophageal squamous cell carcinoma as a model, the specific mechanism of the long-chain non-coding RNA Gas-5 to regulate miRNA-196a is developed, a long non-coding RNA Gas-5 binding site on pri-miRNA-196a and a mechanism to the binding site to interfere the generation of miRNA-196a are made clear, and multiple DGCR8 binding sites on long non-coding RNA Gas-5 and mechanisms of these binding sites to interfere generation of miRNA-196a are also made clear. The binding sites, the binding relationship and the competition relationship provided by the invention can be used for preparing kits and chips for diagnosing and treating esophageal cancer,and a new means for diagnosing and treating esophageal cancer is provided.

The invention discloses a building method of an esophageal squamous cell cancer diagnosis model. The method comprises the following steps that blood serum samples of esophageal cancer and healthy people groups are collected; an LC-MS serum metabolomics technology is adopted for an analysis to obtain an original metabolic fingerprint atlas; the original metabolic fingerprint atlas is subjected to atlas preprocessing and metabolite peak marking to obtain a two-dimensional matrix; information of a diagnosis marker suitable for an esophageal squamous cell cancer early-stage diagnosis is screened out from the two-dimensional matrix to obtain a diagnosis marker two-dimensional matrix; according to the diagnosis marker two-dimensional matrix, a random forest software packet in R language is used for building a random forest model to obtain the esophageal squamous cell cancer diagnosis model. The invention also discloses the diagnosis model and a use method of the diagnosis model. The model building method provided by the invention is simple; the obtained diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for late-stage and early-stage esophagus cancer diagnoses, and has good clinic use and popularization value.

The present invention belongs to the technical field of bioengineering and biomedicine, and specifically relates to the field of oncology and more specifically to a set of early esophageal squamous cell carcinoma screening markers and an application of the markers in a primer probe kit. The present invention provides a primer composition and a probe composition for detecting SLAMF1, CRIM, CCSER1,MGARP, and POMK genes. Besides, the primer composition and probe composition are utilized to prepare the kit for detecting early esophageal squamous cell carcinoma. The detection sensitivity of the kit for the early esophageal squamous cell carcinoma reaches 82.11% and the specificity reaches 86.99%. The kit is suitable for large-scale screening of the early esophageal squamous cell carcinoma of asymptomatic people in a high-incidence area of the esophageal squamous cell carcinoma.

The invention discloses an application of an RNAHsacirc0063865 inhibitor in preparation of a medicine for resisting esophageal squamous cell carcinoma, which is characterized in that the expression level of circular RNA in esophageal squamous cell carcinoma tissue is obviously higher than that in para-carcinoma tissue, and the expression level of the circular RNA in esophageal squamous cell carcinoma cells is changed by constructing Hsacirc0063865 specific siRNAs and other molecular biology means. It is found for the first time that interference on Hsacirc0063865 expression can significantly inhibit proliferation, invasion and migration of esophageal squamous cell carcinoma cells, promote apoptosis of the carcinoma cells and other tumor cell biological phenotypes, so that the Hsacirc0063865 specific siRNAs constructed by the invention can be applied to preparation, screening or treatment of esophageal squamous cell carcinoma or inhibition of esophageal squamous cell carcinoma metastasis, and the application of the Hsacirc0063865 specific siRNAs in preparation, screening or treatment of esophageal squamous cell carcinoma is wide. And a novel treatment method is provided for intervention or treatment of esophageal squamous cell carcinoma.

The invention relates to application of human HHIPL2mRNA in targeted therapy and prognosis evaluation of esophageal squamous cell carcinoma and a kit. According to the invention, abnormal high expression of HHIPL2mRNA in esophageal squamous cell carcinoma tumor tissues is found for the first time, and malignant biological behaviors of esophageal squamous cell carcinoma cell line KYSE-150 cells can be remarkably inhibited by knocking down the expression level of HHIPL2mRNA. The kit comprises siRNA capable of specifically interfering with HHIPL2mRNA expression and a primer pair for detecting the HHIPL2mRNA expression level, and the application of the siRNA and the primer pair in esophageal squamous cell carcinoma targeted therapy strategy development is provided.

The invention relates to the field of biological medicine, in particular to application of menadione in preparation of medicine for treating esophageal squamous cell carcinoma and inhibiting metastasis of esophageal squamous cell carcinoma. The invention provides application of menadione in preparation of a medicine for treating esophageal squamous cell carcinoma. According to the invention, the side effect of menadione is clearer than that of chemotherapeutic drugs, the safety of the drug is proved, and the medicine can be used for treating esophageal squamous cell carcinoma; besides, proliferation of esophageal squamous cell carcinoma cells and transplanted tumors in nude mice can be remarkably inhibited, and the metastasis level of esophageal squamous cell carcinoma cells can be inhibited.